
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99..1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">
<!-- <DIV align="center" style="width: 99%; background: black; padding: 1px; height: 100%"> -->
<!-- <DIV align="center" style="width: 100%; background: white; padding: 5px; height: 100%">  -->


<P align="left" style="margin-right:2%; font-size: 10pt"><FONT style="font-size: 12pt"><U><B>FOR IMMEDIATE RELEASE</B></U></FONT>


<P align="center" style="font-size: 12pt"><B>GUILFORD PHARAMCEUTICALS COMPLETES<BR>
SALE AND LEASEBACK AND RECEIVES $19.4 MILLION IN NET PROCEEDS</B>



<P align="left" style="font-size: 12pt"><B>BALTIMORE, MD</B>, December&nbsp;17, 2004 &#151; Guilford Pharmaceuticals Inc. (Nasdaq: GLFD) today announced
that it has completed a sale and leaseback of its facilities in Baltimore, Maryland with BioMed
Realty Trust, Inc., a real estate investment trust focused on acquiring, owning, leasing and
developing laboratory and office space for life science, biotechnology and pharmaceutical
companies. The net proceeds of this transaction to Guilford were $19.4&nbsp;million. In connection
with this transaction, Guilford has entered into a long-term lease with BioMed for the facilities.
Guilford intends to use the proceeds for general corporate purposes, including providing additional
working capital to support its development pipeline and the continued advancement of the Company&#146;s
AQUAVAN&#174; Injection development program, currently in Phase III clinical testing.


<P align="left" style="font-size: 12pt"><B>About Guilford</B>


<P align="left" style="font-size: 12pt">Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and
commercialization of proprietary drugs that target the hospital and neurology markets. Presently,
Guilford markets two commercial products, GLIADEL<sup>&#174; </sup>Wafer (polifeprosan 20 with
carmustine implant), for the treatment of certain types of brain tumor in combination with
radiation and surgery, and AGGRASTAT<sup>&#174;</sup> Injection (tirofiban hydrochloride), a
glycoprotein GP IIb/IIIa receptor antagonist, for the treatment of acute coronary syndrome (ACS).
Guilford&#146;s product pipeline includes AQUAVAN<sup>&#174;</sup> Injection, an investigational
sedative/anesthetic drug, and drugs for treating peripheral nerve injury. For full prescribing
information, please visit <U>www.guilfordpharm.com</U> under Products / Marketed Products.


<P align="center" style="font-size: 12pt"><FONT style="font-size: 10pt">###</FONT>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="22%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="73%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 10pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-size: 12pt">Contact:</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-size: 12pt">Guilford Pharmaceuticals Inc.<BR>
Stacey Jurchison 410.631.5022<BR>
jurchisons@guilfordpharm.com</FONT></TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 12pt">Internet addresses: www.guilfordpharm.com



<P align="center" style="font-size: 10pt; display: none">


<!-- </DIV> -->
<!-- </DIV> -->
</BODY>

</BODY>
</HTML>

